Virtual Library

Start Your Search

Stephanie Muller



Author of

  • +

    P2.06 - Mesothelioma (Not CME Accredited Session) (ID 955)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.06-40 - VISTA is Highly Expressed in Malignant Pleural Mesothelioma (MPM) and Independent of PD-L1 Expression (ID 13232)

      16:45 - 18:00  |  Author(s): Stephanie Muller

      • Abstract

      Background

      PD-1 blockade is effective in only a minority of MPM patients and predictors of response in MPM are unclear. Recent TCGA analysis of MPM revealed VISTA (V-domain Ig-containing suppressor of T cell activation), another inhibitory T cell checkpoint protein, to be frequently expressed in MPMs. In search of other immunotherapeutic targets in MPM, we evaluated the expression of VISTA, its relationship with expression of PD-L1, and the association with response to PD-1 blockade in MPM.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      We retrospectively interrogated the MPM database at Memorial Sloan Kettering to identify patients who received immune checkpoint inhibitors (ICIs). Archival tissue, where available, was obtained and we performed immunohistochemistry (IHC) using antibodies to PD-L1 (clone E1L3N) and VISTA (clone D1L2G), both from Cell Signaling Technology. Imaging studies were reviewed with a thoracic radiologist according to the modified RECIST criteria.

      4c3880bb027f159e801041b1021e88e8 Result

      37 patients were identified as having received at least one dose of ICI, of whom 26 patients had tissue for VISTA/PD-L1 testing. VISTA was positive (>1%) in 25 (96%) and >50% in 22 (84%). PD-L1 was positive in 11 (42%) and >50% in two (8%). No evident correlation between VISTA and PD-L1 expression was seen. Correlation with response will be reported.

      8eea62084ca7e541d918e823422bd82e Conclusion

      In contrast to PD-L1, VISTA is highly expressed in most patients with MPM. Its expression appears independent of PD-L1 expression. Molecules targeting VISTA and its ligand should be prioritized for clinical development in MPM.

      6f8b794f3246b0c1e1780bb4d4d5dc53